Phase 4 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed by a neurologist to meet the 2024 diagnostic criteria for Multiple Sclerosis (MS), which may include findings from brain or spinal cord scans, eye nerve involvement, or specific markers found in spinal fluid or on MRI
- Adults between 18 and 70 years of age
- People whose MS-related disability level is very low, measured by a standard scale called the EDSS, with a score below 2.5 (confirm with trial site)
- People who are able to give their own informed consent to participate
- People who have an MRI brain scan available that confirms the MS diagnosis and shows fewer than 10 areas of nerve damage (lesions)
- People diagnosed with MS within the past 5 years
- People who are planning to begin treatment with the medication Ublituximab for relapsing MS
Who may not be able to join:
- People who have previously been treated with Mavenclad, Lemtrada, Cyclophosphamide, a stem cell transplant, or similar bone marrow-suppressing treatments
- People who have previously been treated with other B-cell depleting medications, including Ocrelizumab, Rituximab, Ofatumumab, or Inebilizumab
- People who are currently participating in another clinical trial
- People who do not speak a language for which translation services are available within the hospital system
- People whose MS diagnosis or treatment history is not clearly documented
- People who have had a major surgical procedure within the past 6 months
- People with a history of a life-threatening reaction to Ublituximab or a similar medication
- People with active Hepatitis B infection, confirmed by specific blood tests
- People who have received a live or live-attenuated vaccine within 4 weeks before the first dose of the study medication
- People who are in a very advanced stage of illness with a very limited life expectancy (confirm with trial site)
- People who are unable to give consent voluntarily, such as those with reduced decision-making capacity or people who are incarcerated
- People who are unwilling to have blood drawn as part of the study
- People for whom access to Ublituximab through their insurance or health coverage cannot be maintained throughout the full 96-week study period
- People whom the study investigators determine are unable to complete the study activities for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Farrah J Mateen, MD, PhD, Northwestern University
Phone: 630-313-0470
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in plasma neurofilament light chain
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.